Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Free-Cash-Flow-To-The-Firm" stands at 9.80 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Eli Lilly and Company's third quarter result of 8.77 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 485.14 percent compared to it's second quarter result.
Also, Eli Lilly and Company's third quarter result of 8.77 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 3,110.45 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 9.80 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 1,227.73 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 11.37 Billion United States Dollars compared to the value the year prior.
The 1 year change is 11.37 Billion United States Dollars.
The 3 year change is 4.17 Billion United States Dollars.
The 5 year change is 4.44 Billion United States Dollars.
The 10 year change is 7.89 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Johnson & Johnson - Free Cash Flow To The Firm | 486,508,953,600.00 |
![]() | AbbVie Inc - Free Cash Flow To The Firm | 399,570,305,024.00 |
![]() | Roche Holding AG - Free Cash Flow To The Firm | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Free Cash Flow To The Firm | 280,205,508,085.11 |
![]() | Novartis AG - Free Cash Flow To The Firm | 255,096,620,580.91 |